General
Preferred name
GALANTAMINE
Synonyms
Galanthamine hydrobromide ()
GALANTAMINE HYDROBROMIDE ()
Galanthamine ()
Galantamine HBr ()
Galanthamine (hydrobromide) ()
Galantamine (hydrobromide) ()
Galantamine, Nivalin, Razadyne, Razadyne ER, Reminyl, Lycoremine ()
Galanthamine HBr ()
Acumor XL ()
Galzemic XL ()
Galsya XL ()
Gatalin XL ()
Gazylan XL ()
Galantamina ()
Reminyl XL ()
Zeebral XL ()
(-)-galanthamine ()
Consion XL ()
Luventa XL ()
Reminyl ()
NSC-100058 ()
Lotprosin XL ()
(-)-galantamine ()
Elmino XL ()
Razadyne ER ()
Tamilin ()
(-)-galantamine hydrobromide ()
Jilkon hydrobromide ()
Nivaline ()
Nivalin ()
Lycoremine hydrobromide ()
Razadyne ()
Galantamine-d3 (hydrobromide) ()
P&D ID
PD001452
CAS
357-70-0
1953-04-4
1551-02-6
1008759-59-8
69353-21-5
2140262-53-7
Tags
available
drug
Approved by
FDA
First approval
2001
Drug indication
Vascular dementia
Fish-eye disease
Alzheimer disease
Drug Status
approved
Max Phase
4.0
Structure
Probe scores
P&D probe-likeness score
[[ v.score ]]%
Structure formats
[[ format ]]
[[ compound[format === 'MOL' ? 'molblock' : format.toLowerCase()] ]]
Description
(extracted from source data)
PHARMACODYNAMICS Galantamine is a parasympathomimetic, specifically, a reversible cholinesterase inhibitor. It is indicated for the treatment of mild to moderate dementia of the Alzheimer's type, but it is only a disease modifying agent that has little effect in altering the course of the underlying process of dementia. An early pathophysiological feature of Alzheimer's disease that is associated with memory loss and cognitive deficits is a deficiency of acetylcholine as a result of selective loss of cholinergic neurons in the cerebral cortex, nucleus basalis, and hippocampus. Galantamine is postulated to exert its therapeutic effect by enhancing cholinergic function. This is accomplished by increasing the concentration of acetylcholine through reversible inhibition of its hydrolysis by acetylcholinesterase. If this proposed mechanism of action is correct, Galantamine's effect may lessen as the disease progresses and there are fewer cholinergic neurons that remain functionally intact.
DESCRIPTION Many alternative stereo forms exist for the structure. The marketed formulation contains galantamine hydrobromide (PubChem CID 121587). (GtoPdb)
DESCRIPTION Galanthamine is a potent acetylcholinesterase (AChE) inhibitor with an IC50 of 500 nM.
PRICE 29
DESCRIPTION Galanthamine hydrobromide (Galantamine hydrobromide) is a selective, reversible, competitive, alkaloid AChE inhibitor, with an IC50 of 0.35 ¦ÌM. Galanthamine hydrobromide is a potent allosteric potentiating ligand (APL) of human ¦Á3¦Â4, ¦Á4¦Â2, ¦Á6¦Â4 nicotinic receptors ( nAChRs). Galanthamine hydrobromide is developed for the research of Alzheimer's disease (AD)[1][2][3].
DESCRIPTION Galanthamine (Galantamine) is an acetylcholinesterase (AChE)inhibitor(IC50 : 500 nM), can reduce brain damage induced by hypoxia-ischemia. (TargetMol Bioactive Compound Library)
DESCRIPTION MAO-A inhibitor (Tocris Bioactive Compound Library)
DESCRIPTION Cholinesterase inhibitor (Tocriscreen Total)
DESCRIPTION Galantamine is a cholinesterase inhibitor used to manage mild to moderate dementia associated with Alzheimer's Disease. (Enamine Bioactive Compounds)
Cell lines
2
Organisms
0
Compound Sets
34
AdooQ Bioactive Compound Library
A12483
A10416
Cayman Chemical Bioactives
17559
35247
26103
CeMM library of unique drugs (CLOUD)
ChEMBL Approved Drugs
CHEMBL659
CHEMBL1555
ChEMBL Drugs
CHEMBL659
CHEMBL1555
Concise Guide to Pharmacology 2017/18
6693
Concise Guide to Pharmacology 2019/20
6693
Concise Guide to Pharmacology 2021/22
6693
Concise Guide to Pharmacology 2023/24
6693
CZ-OPENSCREEN Bioactive Library
Drug Repurposing Hub
DrugBank
DB00674
DrugBank Approved Drugs
DB00674
DrugCentral
1272
DrugCentral Approved Drugs
1272
DrugMAP
DMEO794
DrugMAP Approved Drugs
DMEO794
Enamine Bioactive Compounds
EBC-13578
Enamine BioReference Compounds
EU-OPENSCREEN Bioactive Compound Library
EOS101393
Guide to Pharmacology
6693
LSP-MoA library (Laboratory of Systems Pharmacology)
CHEMBL659
CHEMBL1555
MedChem Express Bioactive Compound Library
HY-76299
HY-A0009
NCATS Inxight Approved Drugs
0D3Q044KCA
NIH Clinical Collections (NCC)
Novartis Chemogenetic Library (NIBR MoA Box)
NPC Screening Collection
Prestwick Chemical Library
ReFrame library
Selleckchem Bioactive Compound Library
galanthamine
Galanthamine-hydrobromide
TargetMol Bioactive Compound Library
T4S1725
The Spectrum Collection
Tocris Bioactive Compound Library
0686
Tocriscreen Total
External IDs
91
Properties
(calculated by RDKit )
Molecular Weight
287.15
Hydrogen Bond Acceptors
4
Hydrogen Bond Donors
1
Rotatable Bonds
1
Ring Count
4
Aromatic Ring Count
1
cLogP
1.85
TPSA
41.93
Fraction CSP3
0.53
Chiral centers
3.0
Largest ring
7.0
QED
0.8
Structural alerts
0
No structural alerts detected
Related compounds
Custom attributes
(extracted from source data)
MOA
Acetylcholinesterase inhibitor
Inhibitor
Acetylcholinesterase Inhibitors
Butyrylcholinesterase Inhibitors
Target
Acetylcholinesterase
AChE
Apoptosis
ACHE, BCHE, CHRNA1, CHRNA10, CHRNA2, CHRNA3, CHRNA4, CHRNA5, CHRNA6, CHRNA7, CHRNA9, CHRNB1, CHRNB2, CHRNB3, CHRNB4, CHRND, CHRNE, CHRNG
Cholinesterase (ChE)
nAChR
AChR
AChR,ADC Cytotoxin
Primary Target
Cholinesterases
Member status
member
Indication
senile dementia
Pathway
Neuroscience
Neuronal Signaling
Membrane Transporter/Ion Channel
Therapeutic Class
Parasympathomimetics
Source data